Hyperactivating p53 in Human Papillomavirus-Driven Cancers: A Potential Therapeutic Intervention

Despite a vaccine being available, human papillomavirus virus (HPV)-driven cancers remain the ninth most prevalent cancers globally. Current therapies have significant drawbacks and often still lead to poor prognosis and underwhelming survival rates. With gene therapy becoming more available in the...

Descripción completa

Detalles Bibliográficos
Autores principales: Idres, Yusuf M., McMillan, Nigel A. J., Idris, Adi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098605/
https://www.ncbi.nlm.nih.gov/pubmed/35380358
http://dx.doi.org/10.1007/s40291-022-00583-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9098605/
https://www.ncbi.nlm.nih.gov/pubmed/35380358
http://dx.doi.org/10.1007/s40291-022-00583-5

Ejemplares similares